Recommended Global Pulmonology Conferences
Conferenceseries takes immense pleasure to extend our warm welcome to invite all the participants from all over the world to attend "6th International conference on Lung and Respiratory Diseases" which is going to be held during August 31 - September 01, 2018 at Toronto, Canada.The Main theme of the conference is “Optimizing Research Strategies for Lung Disorder Treatments and Innovations in Respiratory Care.”.We invite you to join us at the Lung-2018 conference which will discuss the latest technologies and therapeutic aspects developed for Lung and Respiratory diseases, where you will be sure to have knowledge with scholars from around the world for the paradigm of the Respiratory disorders. It will be a unique opportunity for high quality scientific program with session lectures, symposia, workshops, poster presentations and different programs for participants from throughout the world.
Lung-2018 is a remarkable conference which brings together a unique and International mix of scientists, Researchers, specialists from leading universities and research institutions making the conference a perfect platform to share experience, foster collaboration across industry and academia, and evaluate emerging technologies across the globe.
ConferenceSeries Ltd Organizes 1000+ Conferences every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
- Directors/CEO & Research Scientists
- Pulmonologists, Respiratory Therapists & Pediatricians
- Lung and Respiratory Researchers
- Respiratory Faculty and Students
- Lung and Respiratory Associations and Societies
- Thoracic Surgeons, Radiologists
- Business Entrepreneurs
- Medical and Nursing Students, Professors
- Postdoctoral fellows and Trainees
- Diagnostic laboratory professionals
- Pharmaceutical Professionals
- Medical devices manufacturing companies
- Media representatives
Why to attend?
Meet Your Target Market with members from Toronto and round the world targeted on learning regarding Pulmonology this can be your best chance to achieve the most important assemblage of participants from the Pulmonology community. Conduct demonstrations, distribute information, meet with current and potential customers, create a splash with a new product line, and receive name recognition at this 2-day event. World-renowned speakers, the foremost recent techniques, tactics, and the newest updates in healthcare fields are hallmarks of this conference.
Benefits of attending:
- Meet regional and international healthcare providers, regulators, investors and solution providers for first-hand information on delivering world class healthcare
- Hear from international and regional speakers on global best practice on improving return on investment for healthcare assets
- Participate in roundtable and panel discussion that will inform your operational activities for improved organizational bottom line
- Get certified via in-depth sessions giving your insight into best practices for increasing healthcare facility efficiencies
- Meet with growing healthcare brands and explore partnership opportunities for your business
We hope to see you at Lung-2018!
Sessions And Tracks
Track 1: Respiratory Diseases
Respiratory illness might be a therapeutic term that envelops neurotic conditions moving the organs and tissues that make gas trade feasible in higher life forms, and incorporates states of the higher tract, trachea, bronchi, bronchioles, alveoli, serosa and cavum, and consequently the nerves and muscles of respiratory. Metabolic process ailments differ from delicate and self-constraining, similar to the icy, to horrifying substances like microorganism’s respiratory infection, embolism, intense respiratory sickness and carcinoma.
Track 2: Lung Cancer
Lung cancer starts in the cells of the lung. A cancerous (malignant) tumor is a group of cancer cells that can grow into and destroy nearby tissue. It can also spread (metastasize) to other parts of the body. When cancer starts in lung cells, it is called primary lung cancer. The lung is part of the respiratory system. You use your lungs when you breathe. The lungs are in the chest, one on each side of the heart. The right lung has 3 main parts, called lobes. The left lung is a bit smaller and has 2 lobes. The lungs are cushioned and protected by a thin covering called the pleura. Cells in the lung sometimes change and no longer grow or behave normally. These changes may lead to non-cancerous (benign) tumors such as hamartoma and papilloma. But in some cases, changes to lung cells can cause cancer. Lung cancers are divided into non–small cell lung cancer and small cell lung cancer based on the type of cell in which the cancer started. They are non-small cell lung cancer and small cell lung cancer
- Non-small Cell Lung Cancer
- Small Cell Lung cancer
- What Increases Your Risk
- Exams and Tests
- Treatment Overview
- Surgery and Other Treatment
- Related Information
Track 3: COPD
COPD, or chronic obstructive pulmonary disease, is a progressive disease that makes it hard to breathe. Progressive means the disease gets worse over time COPD can cause coughing that produces large amounts of a slimy substance called mucus, wheezing, shortness of breath, chest tightness, and other symptoms. Cigarette smoking is the leading cause of COPD. Most people who have COPD smoke or used to smoke. However, up to 25 percent of people with COPD never smoked. Long-term exposure to other lung irritants—such as air pollution, chemical fumes, or dusts—also may contribute to COPD. A rare genetic condition called alpha-1 antitrypsin (AAT) deficiency can also cause the disease.
- Diagnostic treatments and Rehabilitation of COPD
- Pathophysiology of COPD
- COPD Risk factors and Management
- COPD Prognosis and Primary care
Track 4: Respiratory and Pulmonary Therapies
A metabolism expert may be a specialized tending professional person UN agency has graduated from a university and passed a national board certifying examination. Metabolism therapists work most frequently in medical aid and operative rooms, however also are usually found in patient clinics and home-health environments.
Respiratory therapists are specialists and educators in medicine and pulmonology. Metabolism therapists also are advanced-practice clinicians in airway management; establishing and maintaining the airway throughout management of trauma, medical aid, and should administer physiological condition for surgery or aware sedation.
- Respiratory Agents
- Occupational lung diseases and therapy
- Respiratory acidosis treatment
- Nutritional approaches to lung disease
- Interventional Pulmonology
Track 5: Prevention of Lung Disorders
As per market standards we have advanced diagnostic techniques like X-Ray and Echocardiogram are to diagnose and identify Lung cancer and Pulmonary Function Testing (PFT) is another test to identify lung cancer disease. This is a medical process involving for this internal examination, biopsy and resection of disease or masses within the pleural cavity and other thoracic cavity. Thoracoscopy may be act either under general anesthesia or sedation with local anesthetic. Surgical biopsy was the standard better way to diagnose of Lung cancer. We have to wear appropriate masks and monitoring exposure to exploring in certain work environments are important precautions to follow. COPD a progressive course causing death from Respiratory failure or difficulties from its associated Lung diseases, which include Respiratory Artery Disease, lung cancer, stroke and Smoking Cessation, is the process of discontinuing tobacco smoking. Tobacco contains nicotine, which is addictive; during the process of quitting very extending and difficult we can control with vaccination and prevention cure.
- Get Vaccinated
- Nutrition to Healthy Lungs
- Breath Matters
- Safe Workplace
- Symptoms around Period
Track 6: Asthma
To understand asthma, it sees however the flying courses work. The avionics courses are tubes that do air into and of your lungs. People who have respiratory sickness have bothered flying courses. The disturbance makes the aeronautics courses swollen and especially fragile. The aeronautics courses tend to react strongly to certain took in substances. Exactly when the aeronautics courses react, the muscles around them settle. This transforms into the avionics courses, conveying less air to stream into the lungs. The swelling can in like manner compound, making the flight courses significantly littler. Cells in the flying courses would maybe make more mucus than anticipated. Release is a sticky, thick liquid that can support thin the avionics courses. This chain reaction can achieve respiratory disorder signs. Symptoms can occur at whatever point the flight courses square measure irritated.
- Asthma prevention and cure: Novel techniques
- Pulmonologist’s and therapeutic care
- Asthma therapy and Types of testing
- Advanced Stages in Asthma allergens
- Stages in asthma detection
- Clinical diagnostics & treatment methods
- Asthma vaccine & drug development
Track 7: Pulmonary Fibrosis and Cystic Fibrosis
Pulmonary Fibrosis is a disease is marked with a scar in the lungs. Tissue deep in the lungs becomes thick, stiff and scarred. Scarring is called fibrosis. As the lung tissue becomes scarred, it interferes with a person's ability to exhale or inhale. In some cases, the cause of pulmonary fibrosis can be found. But most cases of fibrosis have no known cause. This case is called idiopathic pulmonary fibrosis. Cystic Fibrosis is a serious disorder that causes severe damage to the lungs and system. An inherited condition, cystic fibrosis affects the cells that manufacture secretion, sweat and digestive juices. These secreted fluids area unit normally skinny and slippery. However in fibrocystic disease of the pancreas, a defective citron causes the secretions to become thick and sticky. Rather than acting as a material, the secretions plug up tubes, ducts and passageways, especially in the lungs and pancreas. The key difference between Cystic Fibrosis and Pulmonary Fibrosis is that Cystic fibrosis is a genetic disorder where multiple organs including lungs, gastrointestinal system, pancreas as well as the genital system are affected while lung fibrosis is a condition characterized by gradual fibrosis of the lung parenchyma causing defects in the gas diffusion leading to respiratory failure at later stages.
Track 8: Tuberculosis
Tuberculosis is a compelling affliction that overall have an effect the lungs. It is the second most critical killer due to a lone overwhelming authority all through the world, and in 2012, 1.3 million people end from the contamination, with 8.6 million falling wiped out. The tuberculosis bacterium causes TB. It is the degree through the air from individual to person, when people with TB affecting the lungs hack, wheeze, salivation, laugh or talk. TB is powerful, yet it is hard to get. The chances of getting TB from some individual remain alive or work with are significantly higher than from an outcast. The reactions join Coughing, chills, tiredness, Fever, Loss of Weight, and Loss of craving.
- Pathogenesis and Epidemiology of tuberculosis
- Multi Drug Resistance to Tuberculosis
- Current Research in Drugs and Vaccines for tuberculosis
- New treatment Strategies for tuberculosis and HIV
Track 9: cardiopulmonary Disorders
Cardiopulmonary ailment is the therapeutic terms used to depict an alternate social occasion of real issue affecting the heart and lungs. Treatment options move dependent upon the kind of cardiopulmonary infection show and may fuse changes in eating regimen or lifestyle, use of medications issued on arrangement or surgery. The heart and lungs have a comfortable relationship with each other, and issues including one organ may impact the other. For example, a man encountering coronary sickness will encounter issues with capable pumping of blood to oxygenate the lungs. The close-by association between lung limit and heart can achieve different reactions that can realize burdens and may provoke to helpful emergencies, especially when a patient starting at now has diverse honest to goodness prosperity issues.
- Coronary heart disease
- Congestive heart failure
- Rheumatic fever
- Pulmonary Embolism
Track 10: Lung Transplantation
Lung Transplant is surgery to replace one or both diseased lungs with healthy lungs from a human donor. In most cases, the new lung or Lungs are usually donated by a person who is under age 65 and brain-dead, but is still on life-support. The donor tissue must be matched as closely as possible to your tissue type. This reduces the chance that the body will reject the transplant. Lungs can also be given by living donors. Two or more people are needed. Each person donates a segment (lobe) of their Lung Diseases. This forms an entire lung for the person who is receiving it. During Lung Transplant Surgery, you are asleep and pain-free (under general Anesthesia). A surgical cut is made in the chest. Lung Transplant surgery is often done with the use of a heart-Lung Machine. This device does the work of your heart and lungs while your heart and lungs are stopped for the Surgery.
- Post-operative care and Statistics of Transplantation
- Eosinophilic Granuloma
- Chronic Lung Transplantation
- Lung Transplantation Cystic fibrosis
- Lung Rejection
- Bronchiectasis and Lymphangioleiomyomatosis (LAM)
Track 11: Respiratory Tract Infections
Respiratory tract infections (RTIs) are any infection of the sinuses, throat, airways or lungs. They are usually caused by viruses, but can be caused by bacteria. RTIs are thought to be one of the main reasons why people visit their GP or pharmacist. The common cold is the most widespread RTI. Healthcare professionals generally make a difference between them as: Upper respiratory tract infections -- which affect the nose, sinuses and throat, Lower respiratory tract infections – which affect the airway and lungs. Children tend to get more upper RTIs than adults because they haven’t built up immunity (resistance) to many viruses that can cause these infections.
- How respiratory infections spread
- Upper respiratory tract infections
- Lower respiratory tract infections
- Cause, Diagnosis, Treatment and Prevention
Track 12: Sleep Apnea
Sleep Apnea is a rest issue portrayed by stops in breathing or events of shallow unwinding. Apnea is the postponements between breaths. It can continue going for a couple of minutes to a couple of minutes i.e. frequently extraordinary for the body. Additionally, each odd shallow breathing event is named as hypopnea. Rest apnea has been requested into three structures i.e. obstructive (OSA), mixed rest apnea and central rest apnea (CSA). In case breathing is upset by a nonappearance of respiratory effort at that point, it is called as CSA and if, breathing is thwarted by wheezing or by physical piece to wind stream despite respiratory effort at that point, it is kwon as OSA.
- Obstructive Sleep Apnea
- Obstructive Sleep Apnea in Children
- Central Sleep Apnea
- Mixed sleep apnea
- Obstructive Sleep Apnea i Adults
Track 13: Effect of Smoking
Respiratory clutters are most normal therapeutic conditions illnesses on the planet. Some of millions individuals enduring with lung malady in the U.S. Smoking and contaminations, Lung issue are in charge of all lung ailments. The lungs are a piece of human body and it growing and unwinding a large number of times air every day to acquire oxygen and discharging carbon dioxide. Aspiratory Disease can distinguish in any piece of this Respiratory framework. The trachea into tubes called bronchi, which thus branch to wind up noticeably littler tubes in to the lungs.
- Smoking(Long Term Smokers)
- Smoking Lung
- Smoking Pregnancy
- Risk of Smoking
- Smoking Cessation
- Effects of Smoking
- Smoking Heart
- Quit Smoking
Track 14: Advances in Respiratory Medicine
Routine respiratoryorgan perform and metabolism muscletesting ar suggested in youngsters with Neuromuscular Disease (NMD) however these tests are supported non-invasive voluntary man oeuvres, like the measuring of respiratory organ volumes and supreme static pressures, which young youngsters might not forever be able to perform. The conclusion of straightforward natural man oeuvres like a sniff or a cough, and therefore the measuring of esophageal and internal organ pressures throughout spontaneous respiration will add valuable data concerning the strength and endurance of the metabolism muscles in young youngsters. Observation metabolism muscles in youngsters with NMD might improve understanding of the explanation of NMD and therefore the analysis of sickness severity. It’s going to assist and guide clinical management and it's going to facilitate the identification and choice of optimum finish points, also because the most informative Frameworks and patients for clinical trials.
- Management of Idiopathic Pulmonary Fibrosis
- Diagnosing and Staging Lung Cancer Involving the Mediastinum
- Aspiration Related Pulmonary Syndromes
- Respiratory Muscle Testing in Children with Neuromuscular Disease
- Respiratory Syncytial Virus infection and Treatment
Track 15: Advanced Respiratory equipment
In recent years patients with Respiratory diseases use various devices, which help the removal of mucus from the Airways and the improvement of pulmonary function. The aim of the present study is to determine the effectiveness of the current devices of respiratory physiotherapy, as it comes from the review of literature. The current devices of Physiotherapy for patients with Respiratory diseases are presented as an alternative therapy method or a supplemental therapy and they can motivate patients to apply therapy by themselves. These devices seem to increase patients' compliance to daily treatment, because they present many benefits, as independent application, full control of therapy and easy use. These devices are the Positive Expiratory Pressure, the High Frequency Chest Wall Oscillation, the Oral High Frequency Oscillation, and the Intrapulmonary Percussive Ventilation, the Incentive Spirometry the Flutter and the Acapella and the Cornet. Current devices seem to be effective in terms of mucus expectoration and pulmonary function improvement, as it is shown by published studies.
Track 16: Respiratory diseases in children and infants
Respiratory disease is the most common cause of mortality in children in underdeveloped economies and the commonest cause of morbidity in developed economies. Respiratory tract symptoms are particularly prevalent in young children and evidence for the relative contributions of potentially remediable environmental factors is emerging. The state of children’s respiratory health is determined by the interaction of many factors including potential stressors from their environment, patterns of exposure, individual vulnerability and genetics. Identifiable risk factors include infection, air pollution (indoors and outdoors), diet, lifestyle, social condition, occupation, and provision of medical care. They produce a multi-causal effect that has both short- and longer-term manifestations with implications for lifelong respiratory health. This effect varies with gender, developmental age and ethnicity.
- Acute Bronchitis
- Perinatal respiratory diseases and BPD
- Severe Community- acquired pneumonia in children
- Congenital respiratory disorders
- Pediatric Aspiration Syndromes
- Infant respiratory distress syndrome
The term lung disease refers to many disorders affecting the lungs, such as asthma, COPD, infections like influenza, pneumonia and tuberculosis, lung cancer, and many other breathing problems. Some lung diseases can lead to respiratory failure.
Respiratory drug market
The global respiratory drugs market is expected to reach around $65 billion in 2020. Going forward, the rise in global air pollution levels will lead to higher number of respiratory diseases thus driving the respiratory drugs market. Respiratory diseases drugs market covers drugs that are used in the treatment of a wide range of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), chronic and acute bronchitis, emphysema and cystic fibrosis. Some of the major drugs in the market include antimuscarinics, corticosteroids, Codral, Coldrex and Lemsip. The market numbers in this briefing cover pharmaceutical (drug) treatments and do not cover biologic treatments for these conditions which are included in a separate briefing. Growing Demand For Tamper-Resistant Pseudoephedrine (PSE) Products - The demand for PSE-containing cold, allergy, and sinus products is growing due to their effectiveness and convenience. PSE is an active ingredient found in various cold, allergy, and sinus drugs that can provide congestion relief. However, PSE-containing medicines are mostly sold as a prescription drug, as PSE can also be used for the illegal manufacture of methamphetamine, a recreational drug. This has led drug manufacturers to produce tamper-resistant PSE products.
The USA's respiratory devices market is currently estimated to be worth USD 1.98 billion in 2014 and is expected to reach USD 3.44 billion by the end of 2019. The CAGR during this period of the forecast is projected to be 11.98%.
This escalation is developing the need to analyze, review and forecast the growth of the respiratory devices market. Owing to the rapid evolution of the market in the use of CPAP devices, medical device companies that are able to launch new innovative equipment will be rewarded with huge benefits.
U.S. therapeutic respiratory devices market share was over 60% of industry revenue in 2015, estimated to grow at 10.8% CAGR from 2016 to 2024. Increasing COPD prevalence, presence of baby boomer population base and favorable reimbursement scenario will stimulate regional growth.
Why in Toronto?
North America’s fourth-largest city, Toronto buzzes with 200,000 students and a population representing 200 nations. As well as ethnic restaurants, the food scene features some of Canada’s best chefs, all following the “fresh and local” mantra. Getting around is easy on the efficient transport system; Niagara Falls are two hours away. Toronto is fun. With top-notch restaurants and theatre, museums and art galleries, there is plenty to see and do. The downtown skyscrapers mark Canada’s financial hub, but after hours, business folk swap suits for shorts and head outside in summer; in winter, they pull on parkas and ice skates.
Two decades ago, Canadians would have laughed at the idea of the provincial capital being a fun place to visit. Today, one of North America’s safest cities hosts visitors from around the world. Perhaps their best souvenir is memories of Torontonians themselves: welcoming, ready to help, with a smile.
Toronto’s variety is surprising. The 1,815-ft CN Tower provides astonishing views over Lake Ontario. Below, Toronto’s cultural scene hums, with theatre, ballet and lives music nightly in dozens of pubs. Classy museums include the Art Gallery of Ontario the Royal Ontario Museum and the quirky Bata Museum, all about shoes. Have fun in the Distillery District; buy funky fashion along Queen Street West; munch your way round Market and St Lawrence Market.
Canada Respiratory Devices Market
Canada’s respiratory devices market is currently estimated to be worth USD 1.36 billion in 2017 and is expected to reach USD 2.38 billion by the end of 2019. The CAGR during this period of the forecast is projected to be 11.83%.
This escalation is developing the need to analyze, review and forecast the growth of the respiratory devices market. Owing to the rapid evolution of the market in the use of CPAP devices, medical device companies that are able to launch new innovative equipment will be rewarded with huge benefits.
Canada Respiratory Devices Market-Market Dynamics
The report details several factors driving and restraining the market for respiratory devices. Some of these are listed below.
Some factors contributing to the growth of the market are:
- Large patient population
- Increase in the technological advancements
- Increased disposable income in developing nations
- Rising incidence of Chronic Obtrusive Pulmonary Disease(COPD)
Expensive devices and increased sophistication in the use of the devices are the major challenges faced by the respiratory devices market.
The report studies the markets for different respiratory devices, which include humidifiers, resuscitators, breathing circuits, chambers, CPAP devices, masks, oxygen concentrators, nebulizers, ventilators, inhalers, tracheostomy tubes, oxygen cannulas, capnographs, and spirometers. The CPAP devices currently dominate the respiratory device market and are expected to dominate it in the future also.
Region wise Respiratory Devices Market:
What the Report Offers
- Market analysis for Canada’s respiratory devices market, with region-specific assessments and competition analysis on the global and regional scale.
- Market definition along with the identification of key drivers and restraints.
- Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale.
- Extensively researched competitive landscape section with profiles of major companies along with their market share for the next five years.
- Identification and analysis of the macro and micro factors that affect the market on both global and regional scale.
- A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
- A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market.
- Insights on the major countries/regions where this industry is blooming and to also identify the regions that are still untapped.
- The various applications of respiratory devices have been discussed in detail, in addition to a comprehensive overview of the market.
The incidence, morbidity and mortality of chronic obstructive pulmonary disease (COPD) are rising throughout the world. The total economic cost of COPD in the US in 1993 was estimated to be over $US15.5 billion, with $US6.1 billion for hospitalisation, $US4.4 billion for physician and other fees, $US2.5 billion for drugs, $US1.5 billion for nursing home care and $US1.0 billion for home care. Office visits, hospital outpatient visits and emergency department visits accounted for 17.3% of the direct costs for COPD in the US. When stratified by severity, COPD treatment costs strongly correlate with disease severity.
The American Thoracic Society, the European Respiratory Society and the British Thoracic Society have developed guidelines for the pharmacological treatment of COPD. However, the guidelines establish inhaled bronchodilators (anticholinergic agents and beta 2-adrenergic agonists) as the mainstay of therapy for patients with COPD. The guidelines were not based on cost analyses and thus are not a priori cost-effective guidelines. Since the publication of these guidelines, several new pharmacological products have been approved for use in patients with COPD including a combination of an anticholinergic and selective beta 2-adrenergic agonist [ipratropium/salbutamol (albuterol)] and a long-acting beta 2-adrenergic agonist (salmeterol). Both products are effective bronchodilators in COPD.
The purpose of this report is to place these new agents in an updated pharmacological guideline scheme, utilizing recently published data on clinical efficacy as well as pharmacoeconomics. The annualized healthcare costs were computed to be $US788/patient/year for the combination ipratropium/salbutamol inhaler and $US1059/patient/year for salmeterol (1999 values). Based upon an improved understanding of the complexity of COPD, the response of patients to newer bronchodilators (given individually or in combination), and recent pharmacoeconomic data for COPD treatment, a new treatment algorithm with associated costs is proposed. The use of an algorithm, based on medical and pharmacoeconomic data, will improve lung function in patients with COPD, improve patient satisfaction (e.g. quality of life, dyspnea) and outcomes (e.g. exacerbations).
Lung cancer is by far the most common cause of cancer death in Nevada, killing almost 50 out of every 100,000 people in Nevada in 2008. About 31% of cancer deaths among men and 26% among women are from lung cancer. Lung cancer deaths have historically been higher among whites, while rates have been lowest among Hispanics and Asians.
- Symptoms of Pulmonary Disorders
- Pulmonary Function Testing and Diagnosis
- Acute Bronchitis
- Asthma and Related Disorders
- Bronchiectasis and Atelectasis
- COPD and Related Disorders
- Pulmonary Vascular Disease
- Diffuse Alveolar Hemorrhage
- Environmental Pulmonary Diseases
- Lung Diseases
- Pleural Effusion
- Pulmonary Embolism
- Sleep Apnea
- Pulmonary Research
- Pulmonary Rehabilitation
Novel Approach and Therapies
- Over the course of the seven years of the study, 22 research centers around the North American countries, enrolled and treated participants. Thirteen centers participated for the majority of the active project, and participants from these centers comprise 90 percent of the total number enrolled.
- Baylor College of Medicine; Houston, TX Principal Investigator, Lauren B. Marangell, MD
- Case Western Reserve University; Cleveland, OH Principal Investigator, Joseph R. Calabrese, MD
- University of Colorado Health Sciences Center; Denver, CO Principal Investigator, Michael Allen, MD
- University of Louisville School of Medicine; Louisville, KY Principal Investigator, Rif El-Mallakh, MD
- Massachusetts General Hospital and Harvard School of Medicine; Boston, MA Principal Investigator, Andrew A. Nierenberg, MD
- University of Massachusetts Medical School; Worcester, MA Principal Investigator, Jayendra Patel, MD
- University of Missouri School of Medicine; Kansas City, MO Principal Investigator, Kemal Sagduyu, MD
- University of Oklahoma College of Medicine - Tulsa; Tulsa, OK Principal Investigator, Mark D. Fossey, MD
- University of Pennsylvania School of Medicine and Medical Center; Philadelphia, PA Principal Investigator, Laszlo Gyulai, MD
- University of Pittsburgh Western Psychiatric Institute and Clinic; Pittsburgh, PA Principal Investigator, Michael E. Thase, MD
- Portland Veteran’s Administration Medical Center; Portland, OR Principal Investigator, Peter Hauser, MD
- Stanford University School of Medicine; Stanford, CA Principal Investigator, Terence A. Ketter, MD
- University of Texas Health Science Center at San Antonio, San Antonio, TX Principal Investigator, Charles Bowden, MD
Additional centres involved involves in respiratory education are: Howard University, Washington DC; Rush-Presbyterian St. Luke’s Medical Center, Chicago, IL; State University of New York at Buffalo, Buffalo, NY; Weill Medical College of Cornell University and New York Presbyterian Hospital, NY, NY; New York University School of Medicine, NY, NY; University of California San Diego, La Jolla, CA; University of Arizona, Tucson, AZ; and Medical University of South Carolina, Charleston, SC.
Major Associations around the Globe for Lung and Respiratory Diseases.
- Alabama Society for Respiratory Care
- Alaska Society for Respiratory Care
- Associazione Scientifica Interdisciplinare per lo Studio delle Malattie Respiratorie (AIMAR) (Italy)
- Associazione Italiana Pneumologi Ospedalieri (AIPO) (Italy)
- American Association for Respiratory Care (AARC) (United States)
- American College of Chest Physicians (ACCP) (United States)
- American Thoracic Society (ATS) (United States)
- Asian Pacific Society of Respirology (APSR)
- Asociación Argentina de Medicina Respiratoria (Argentina)
- Associación Latin Americana del Tórax (ALAT)
- Austrian Society of Pneumology (ASP) (Austria)
- Belgian Thoracic Society
- Brazilian Thoracic Society
- British Thoracic Society
- Bulgarian Society of Respiratory Diseases
- California Society for Respiratory Care
- Canadian Society for Respiratory Therapy
- Canadian Thoracic Society
- Croatian Respiratory Society
- Colorado Society for Respiratory Care
- Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin e.V. (Germany)
- Dutch Thoracic Society (NVALT)
- European Respiratory Society (ERS)
- Egyptian Society of Chest Diseases and Tuberculosis
- European Society of Thoracic Imaging (ESTI)
- Estonian Respiratory Society
- European Academy of Allergology and Clinical Immunology (EAACI)
- European Federation of Allergy and Airways Diseases Patients’ Associations (EFA)
- European Lung Foundation (ELF) ( World Spirometry Day (WSD) )
- Global Smoke Free Partnership (GSP)
- Hellenic Thoracic Society (Greece)
- Hungarian Respiratory Society
- Indian Chest Society
- International Society for Aerosolin Medicine (ISAM)
- Irish Thoracic Society
- Kazakhstan National Respiratory Society (Kazakhstan)
- Kyrgyz Thoracic Society
- Latvian Society of Lung Physicians
- Lebanese Pulmonary Society
- Médecins sans frontières (MSF) (Doctors Without Borders)
- Moroccan Society of Allergy and Clinical Immunology
- National Research Institute of Tuberculosis and Lung Disease (Iran)
- National Board for Respiratory Care (NBRC)
- Pakistan Chest Society
- Pan African Thoracic Society (PATS)
- Polish Respiratory Society
- Primary Care Respiratory Journal (PCRJ)
- Romanian Society of Pneumology
- Russian Respiratory Society
- Saudi Thoracic Society
- Schweizerische Gesellschaft für Pneumologie (Switzerland)
- Slovak Pneumological and Ftiseological Society
- Slovenian Respiratory Society
- Sociedad Chilena de Enfermedades Respiratorias (Chile)
- Sociedad Española de Neumología y Cirugía Torácica (Spain)
- Sociedade Portuguesa de Pneumologia (Portugal)
- Société Algérienne de Pneumophtisiologie (Algeria)
- Société de Pneumologie de Langue Française (SPLF)
- Society of Albanian Pulmonologists
- South African Thoracic Society
- Taiwan Society of Pulmonary and Critical Care Medicine
- Texas Society for Respiratory Care
- The European Association for Cardio-Thoracic Surgery (EACTS)
- The Finnish Respiratory Society
- The Japanese Respiratory Society
- Tunisian Society of Respiratory Disease and Allergology
- Turkish Respiratory Society
- Turkish Thoracic Society
- Respiratory Therapist
- Respiratory practitioner
- Respiratory Care Practitioner (RCP)
- Respiratory scientist
- Respiratory Nurse
- Respiratory Physiotherapist
- Clinical Respiratory Physiologist
- Physician assistant\
Respiratory Care Devices Market worth 21.9 Billion USD by 2020
The respiratory care devices market is growing at a significant rate since the last decade. Growth in this market is mainly attributed to the high prevalence of respiratory diseases, rising aging population across the globe, high prevalence of smoking, rising urbanization and pollution levels, increasing incidences of preterm births, and lifestyle changes. However, lack of awareness and harmful effects of certain respiratory care devices on neonates are the major challenges in this market.
In this report, the respiratory care devices market is segmented on the basis of products and end users. On the basis of products, the respiratory care devices market is segmented into therapeutic devices, monitoring devices, diagnostic devices, and consumables & accessories. The therapeutic devices segment is further divided into humidifiers, nebulizers, oxygen concentrators, positive airway pressure (PAP) devices, reusable resuscitators, ventilators, inhalers, masks, nitric oxide delivery units, and oxygen hoods. The monitoring devices segment is categorized into pulse oximeters, capnographs, and gas analyzers. The diagnostics devices segment is subdivided into spirometers, peak flow meters, polysomnography (PSG) devices, and other diagnostic devices; while, the consumables and accessories segment is categorized into disposable masks, disposable resuscitators, tracheostomy tubes, nasal cannulas, and other consumables & accessories.
In 2014, the therapeutic devices segment accounted for the largest share of the global respiratory care devices market. The large share of this segment is mainly attributed to the rising adoption of various therapeutic devices such as nebulizers, oxygen concentrators, humidifiers, and PAP devices due to growth in the elderly population and rising prevalence of respiratory diseases.
On the basis of end users, the respiratory care devices market is bifurcated into hospitals and home care. Hospitals are the major end users of the global respiratory care devices market, owing to the financial capabilities of hospitals to purchase high-end instruments as well as the availability of trained professionals to operate respiratory care devices.
On the basis of regions, the respiratory care devices market is broadly segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. Highly developed healthcare systems and rising healthcare expenditures are the major factors responsible for the large shares of North America and Europe in the global respiratory care devices market. However, the Asia-Pacific region is expected to grow at the highest CAGR, owing to the presence of a large pool of respiratory patients, increasing healthcare expenditure, rapidly developing healthcare infrastructure, increasing per capita incomes, and growing middle-class population in emerging countries of this region.
Major players in the global respiratory care devices market include Philips Healthcare (Netherlands), ResMed, Inc. (U.S.), Covidien plc (Ireland), Masimo Corporation (U.S.), Fisher and Paykel Healthcare Limited (New Zealand), and CareFusion Corporation (U.S.).
Lung and related respiratory diseases:
Pulmonary Disease is very common. Approximately 12 million adults in the U.S. are diagnosed with pulmonary disease, and 120,000 die from it each year. An additional 12 million adults in the U.S. are thought to have undiagnosed pulmonary disease. Pulmonary Disease death rates for women have risen steadily. Today, more women than men die from pulmonary disease each year. Today, spirometry is widely available to doctors in primary care settings, facilitating earlier diagnosis of pulmonary disease. Doctors now recognize that nicotine addiction makes it very difficult for people to stop smoking. Fortunately, methods for smoking cessation have improved, and smokers can benefit from effective treatments and counseling to overcome nicotine addiction.
A wide range of treatments are now available to improve the quality and length of life for pulmonary disease patients, including vaccinations against influenza and pneumonia, inhaled bronchodilator drugs, pulmonary rehabilitation, oxygen therapy, and surgical interventions. Glucocorticoids and antibiotics are regularly used to treat acute exacerbations of pulmonary disease.
Several NIH-sponsored research programs have increased understanding of pulmonary disease and fostered new treatments. For example, the Nocturnal Oxygen Therapy Trial showed that some patients with advanced pulmonary disease live longer if given long-term oxygen therapy. The Lung Health Study showed that a smoking cessation intervention can improve long-term survival of Pulmonary Disease patients. The National Emphysema Treatment Trial (NETT) (http://www.nhlbi.nih.gov/health/prof/lung/nett/lvrsweb.htm) showed that lung-volume-reduction surgery can improve the quality and/or length of life in certain groups of patients with severe pulmonary disease. Although researchers continue to investigate the role of proteases in pulmonary disease, new findings suggest strong inflammatory and immune components to pulmonary disease. This insight led to a variety of new ideas about Pulmonary Disease treatment and has stimulated a surge in research activity.
Despite rapidly rising illness and death rates due to pulmonary disease, awareness of pulmonary disease among the general public and those at greatest risk for the disease remains low.
To promote public awareness of pulmonary disease, the NIH is partnering with patient advocacy groups and health professional organizations on a pulmonary disease awareness and education campaign called pulmonary disease: Learn More, Breathe Better (http://www.nhlbi.nih.gov/health/public/lung/Pulmonary Disease/lmbb-campaign/index.htm). The campaign focuses on increasing knowledge of symptoms, diagnosis, and treatment among pulmonary disease patients and people at risk of developing pulmonary disease.
It is now recognized that 10-20% of pulmonary disease patients have never smoked! Furthermore, only a fraction of smokers develop pulmonary disease, suggesting that both genetic and environmental factors influence the risk of developing pulmonary disease. Investigators in the pulmonary disease gene Study will recruit 10,000 smokers and nonsmokers to identify the genetic factors that determine why some people develop pulmonary disease and others do not.
Pulmonary Disease is a complex disease that presents in many different ways. The NIH is supporting research to help tailor therapies for pulmonary disease to individual patients. A study called SPIROMICS (subpopulations and intermediate outcome measures in pulmonary disease study) will use genetic data, genomic information, and analyses of phenotypes and biomarkers to determine how pulmonary disease differentially affects patient subpopulations.
The NIH pulmonary disease Clinical Research Network (CCRN) is performing therapeutic trials in patients with moderate to severe pulmonary disease, with an emphasis on preventing and managing exacerbations. One study is comparing the effectiveness of two different pneumococcal vaccines in patients with pulmonary disease. Another study will determine whether an antibiotic called azithromycin is useful in reducing the severity and number of exacerbations. In addition, statin drugs, best known for their use in lowering cholesterol, are being evaluated for their possible role in preventing or diminishing pulmonary disease exacerbations.
The NIH, in cooperation with the Centers for Medicare and Medicaid Services, is supporting the Long-Term Oxygen Treatment Trial (LOTT) to determine whether supplemental oxygen is beneficial to patients with milder disease than those studied previously. The NIH also supports the Lung Tissue Research Consortium (LTRC), which provides lung tissue specimens to qualified researchers investigating the biological basis of PULMONARY DISEASE and other lung diseases.
The NIH supports research to improve understanding of the disease process in pulmonary disease, identify pivotal points in its onset and progression, and provide the knowledge base needed to intervene early and prevent its development or progression.
Past Conference Report
Conferenceseries successfully hosted for "International conference and Exhibition on Lung and Respiratory Care" during July 13-14, 2015 Baltimore, USA. Lung 2015 conference was organized around the theme “Optimizing research strategies for breakthrough innovations in Lung disorders treatment" and it was a great success where eminent keynote speakers from various reputed organizations made their resplendent presence and addressed the gathering.
Lung 2015 was marked by the attendance of Editorial Board Members of supported Journals like Journal of Pulmonary & Respiratory Medicine, Journal of Mycobacterial Diseases and Journal of General Medicine. Many Scientists, young and brilliant Researchers, Business Delegates and talented Student Communities representing from varies countries made this conference fruitful and productive driving the two-day event into the path of success with thought provoking keynote and plenary presentations.
International conference and Exhibition on Lung and Respiratory Care covered the following scientific sessions and discussions:
- Lung and Respiratory Metabolism
- Lung and Respiratory Infections
- Lung Disorders
- Pulmonary Tuberculosis
- Pulmonary Disease: Pneumonia
- Lung Cancer and Treatment Strategies
- Respiratory Tract and Associated Defense Mechanisms
- Biological and Pathological Effects
- Advanced Diagnostic Techniques for Lung Disorders
- Prevention, Cure and Control Management of Lung Disorders
- Novel and Futuristic Research Aspects and Clinical Trails
We are also obliged to various delegate experts, company representatives and other eminent personalities who supported the conference by facilitating active discussion forums. We sincerely thank the Organizing Committee Members for their gracious presence, support and assistance towards the success of Lung 2015. With the feedback from the participants and supporters of Lung 2015 Conferenceseries is glad to announce 6th International Conference on Lung and Respiratory Diseases (Lung 2018) during Aug 31 – Sept 01, 2018 in Toronto, Canada.
Past Reports Gallery Lung 2016
Conferenceseries successfully hosted for "4th International conference and Exhibition on Lung and Respiratory Care" during August 01-02, 2016 Manchester, UK. Lung 2016 conference was organized around the theme "Optimizing Research Strategies for Lung Disorder Treatments and Innovations in Respiratory Care" and it was a great success where eminent keynote speakers from various reputed organizations made their resplendent presence and addressed the gathering.
Lung 2016 was marked by the attendance of Editorial Board Members of supported Journals like Journal of Pulmonary & Respiratory Medicine, Journal of Mycobacterial Diseases and Journal of Lung Cancer Diagnosis and Treatment. Many Scientists, young and brilliant Researchers, Business Delegates and talented Student Communities representing from varies countries made this conference fruitful and productive driving the two-day event into the path of success with thought provoking keynote and plenary presentations.
5th International conference and Exhibition on Lung and Respiratory Care covered the following scientific sessions and discussions:
- Lung Cancer
- Tuberculosis Infections
- Bronchial Asthma
- Pulmonary Diseases and Therapeutics
- Lung Infection
- Respiratory Tract Infections
- Respiratory Equipment Diseases
- Control of Respiratory Diseases
- Diagnostic Techniques of Lung Disorders
- Tobacco Smoking
- Cystic Fibrosis
- Pulmonary Infection Test
- Lung Transplantation
We are also obliged to various delegate experts, company representatives and other eminent personalities who supported the conference by facilitating active discussion forums. We sincerely thank the Organizing Committee Members for their gracious presence, support and assistance towards the success of Lung 2016. With the feedback from the participants and supporters of Lung 2016 Conferenceseries is glad to announce 6th International Conference on Lung and Respiratory Diseases (Lung 2018) during Aug 31 – Sept 01, 2018 in Toronto, Canada.
Past Reports Proceedings Gallery